Stanford Cancer Institute, CA, USA.
J Natl Compr Canc Netw. 2012 Jul 1;10(7):821-9. doi: 10.6004/jnccn.2012.0086.
These NCCN Guidelines Insights highlight the important updates/changes specific to the management of metastatic breast cancer in the 2012 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer. These changes/updates include the issue of retesting of biomarkers (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) on recurrent disease, new information regarding first-line combination endocrine therapy for metastatic disease, a new section on monitoring of patients with metastatic disease, and new information on endocrine therapy combined with an mTOR inhibitor as a subsequent therapeutic option.
这些 NCCN 指南洞察突出了 2012 版 NCCN 肿瘤学临床实践指南（NCCN 指南）中乳腺癌部分中转移性乳腺癌管理的重要更新/变化。这些变化/更新包括复发疾病中生物标志物（雌激素受体、孕激素受体和人表皮生长因子受体 2）的重新检测问题、转移性疾病一线联合内分泌治疗的新信息、转移性疾病患者监测的新章节以及内分泌治疗联合 mTOR 抑制剂作为后续治疗选择的新信息。
